Hyoscine for Epigastric Pain: Limited Evidence and Not First-Line
Hyoscine (scopolamine/hyoscine butylbromide) is not specifically recommended for epigastric pain in current gastroenterology guidelines, and the available evidence does not support its use as a primary treatment for this indication.
Guideline Perspective
The British Society of Gastroenterology guidelines on functional dyspepsia 1 define epigastric pain syndrome (EPS) as a distinct subtype of functional dyspepsia characterized by epigastric pain or burning that occurs regardless of meals. However, these guidelines do not mention hyoscine as a recommended treatment option for epigastric pain. Similarly, the AGA clinical practice update on chronic gastrointestinal pain 2 emphasizes neuromodulators (tricyclic antidepressants, SNRIs) and nonpharmacologic therapies for disorders of gut-brain interaction, but does not include anticholinergics like hyoscine in their management algorithm.
Evidence for Hyoscine in Abdominal Pain
The research evidence for hyoscine is primarily focused on cramping, spasmodic abdominal pain rather than epigastric pain specifically:
Supporting Evidence (for cramping pain):
- Hyoscine butylbromide showed efficacy for gastric or intestinal spasm-like pain in Chinese patients, with pain reduction of approximately 59% within 180 minutes 3, 4
- For functional cramping abdominal pain, on-demand hyoscine (20-100 mg/day) achieved clinically relevant pain reduction (≥2 points on 11-point scale) within 45 minutes versus 60 minutes for placebo 5
- In severe IBS with predominant cramping pain, intramuscular hyoscine provided substantial pain relief in 62% of patients and allowed 32% to reduce or stop opiates 6
Contradictory Evidence:
- Most recent high-quality study: A 2024 double-blind RCT found that intravenous hyoscine butylbromide (20 mg) showed no significant difference compared to placebo for abdominal cramping pain in acute gastroenteritis at both 30 and 60 minutes 7
- In pediatric nonspecific colicky abdominal pain, hyoscine was not superior to acetaminophen 8
Critical Distinction: Cramping vs. Epigastric Pain
The key issue is that epigastric pain (as defined in functional dyspepsia) is typically described as burning or aching pain in the upper abdomen, not cramping or spasmodic pain. Hyoscine is an anticholinergic antispasmodic that works by inhibiting smooth muscle contractility 3. This mechanism is theoretically suited for cramping, colicky pain rather than the burning epigastric pain characteristic of EPS.
Safety Considerations
The FDA label notes 9:
- Safety in pregnancy and lactation not established
- Common adverse effects include dry mouth, thirst, and anticholinergic symptoms 9, 3
- Generally well-tolerated with infrequent serious adverse events
Clinical Recommendation
For true epigastric pain (burning, non-cramping upper abdominal pain):
- Follow guideline-directed therapy for functional dyspepsia, which typically includes proton pump inhibitors, H. pylori eradication if present, and neuromodulators for refractory cases 1, 2
- Hyoscine should not be considered first-line
If the pain has a cramping, spasmodic quality:
- Hyoscine butylbromide may be considered as an on-demand option (10-20 mg orally)
- However, be aware that the most recent evidence 7 questions its efficacy even for cramping pain
- Alternative antispasmodics or acetaminophen may be equally effective 8
Common pitfall: Assuming all "epigastric pain" is the same. Carefully characterize whether the pain is burning (typical of dyspepsia/EPS) versus cramping (where antispasmodics might theoretically help, though evidence is mixed).